English
简体中文
Total: £ 56.28
Published Date: 2025-10-17 | Pages: 134 | Tables: 142 | Medical Care
The global Non-Invasive Prenatal DNA Testing Service market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
The non-invasive prenatal DNA testing service collects peripheral venous blood from pregnant women, uses the next-generation DNA sequencing technology to sequence the free DNA fragments (including fetal free DNA) in the maternal peripheral plasma, and performs bioinformatics analysis on the sequencing results to obtain the genetic information of the fetus and detect whether the fetus has a chromosomal disease.
From a downstream perspective, Hospitals accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Non-Invasive Prenatal DNA Testing Service leading manufacturers including Natera Inc, Illumina, Roche, GE Healthcare, Thermo Fisher Scientific, Perkinelmer, Qiagen, Agilent Technologies, Veritas, BGI Group, etc., dominate supply; the top five capture approximately % of global revenue, with Natera Inc leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Non-Invasive Prenatal DNA Testing Service market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Natera Inc
Illumina
Roche
GE Healthcare
Thermo Fisher Scientific
Perkinelmer
Qiagen
Agilent Technologies
Veritas
BGI Group
Annoroad
Segment by Type
Serum Biochemical Index Detection
Maternal Peripheral Blood Free DNA Detection
Ultrasound Screening
Segment by Application
Hospitals
Medical Institutions
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Non-Invasive Prenatal DNA Testing Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Non-Invasive Prenatal DNA Testing Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Non-Invasive Prenatal DNA Testing Service Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Serum Biochemical Index Detection
1.2.3 Maternal Peripheral Blood Free DNA Detection
1.2.4 Ultrasound Screening
1.3 Market Segmentation by Application
1.3.1 Global Non-Invasive Prenatal DNA Testing Service Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Medical Institutions
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Non-Invasive Prenatal DNA Testing Service Revenue Estimates and Forecasts 2020-2031
2.2 Global Non-Invasive Prenatal DNA Testing Service Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Non-Invasive Prenatal DNA Testing Service Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Non-Invasive Prenatal DNA Testing Service Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Serum Biochemical Index Detection Market Size by Players
3.3.2 Maternal Peripheral Blood Free DNA Detection Market Size by Players
3.3.3 Ultrasound Screening Market Size by Players
3.4 Global Non-Invasive Prenatal DNA Testing Service Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Non-Invasive Prenatal DNA Testing Service Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Non-Invasive Prenatal DNA Testing Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Non-Invasive Prenatal DNA Testing Service Market Size by Type (2020-2031)
6.4 North America Non-Invasive Prenatal DNA Testing Service Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Non-Invasive Prenatal DNA Testing Service Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Non-Invasive Prenatal DNA Testing Service Market Size by Type (2020-2031)
7.4 Europe Non-Invasive Prenatal DNA Testing Service Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Non-Invasive Prenatal DNA Testing Service Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Non-Invasive Prenatal DNA Testing Service Market Size by Type (2020-2031)
8.4 Asia-Pacific Non-Invasive Prenatal DNA Testing Service Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Non-Invasive Prenatal DNA Testing Service Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Non-Invasive Prenatal DNA Testing Service Market Size by Type (2020-2031)
9.4 Central and South America Non-Invasive Prenatal DNA Testing Service Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Non-Invasive Prenatal DNA Testing Service Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Non-Invasive Prenatal DNA Testing Service Market Size by Type (2020-2031)
10.4 Middle East and Africa Non-Invasive Prenatal DNA Testing Service Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Non-Invasive Prenatal DNA Testing Service Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Natera Inc
11.1.1 Natera Inc Corporation Information
11.1.2 Natera Inc Business Overview
11.1.3 Natera Inc Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.1.4 Natera Inc Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.1.5 Natera Inc Non-Invasive Prenatal DNA Testing Service Revenue by Product in 2024
11.1.6 Natera Inc Non-Invasive Prenatal DNA Testing Service Revenue by Application in 2024
11.1.7 Natera Inc Non-Invasive Prenatal DNA Testing Service Revenue by Geographic Area in 2024
11.1.8 Natera Inc Non-Invasive Prenatal DNA Testing Service SWOT Analysis
11.1.9 Natera Inc Recent Developments
11.2 Illumina
11.2.1 Illumina Corporation Information
11.2.2 Illumina Business Overview
11.2.3 Illumina Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.2.4 Illumina Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.2.5 Illumina Non-Invasive Prenatal DNA Testing Service Revenue by Product in 2024
11.2.6 Illumina Non-Invasive Prenatal DNA Testing Service Revenue by Application in 2024
11.2.7 Illumina Non-Invasive Prenatal DNA Testing Service Revenue by Geographic Area in 2024
11.2.8 Illumina Non-Invasive Prenatal DNA Testing Service SWOT Analysis
11.2.9 Illumina Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview
11.3.3 Roche Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.3.4 Roche Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.3.5 Roche Non-Invasive Prenatal DNA Testing Service Revenue by Product in 2024
11.3.6 Roche Non-Invasive Prenatal DNA Testing Service Revenue by Application in 2024
11.3.7 Roche Non-Invasive Prenatal DNA Testing Service Revenue by Geographic Area in 2024
11.3.8 Roche Non-Invasive Prenatal DNA Testing Service SWOT Analysis
11.3.9 Roche Recent Developments
11.4 GE Healthcare
11.4.1 GE Healthcare Corporation Information
11.4.2 GE Healthcare Business Overview
11.4.3 GE Healthcare Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.4.4 GE Healthcare Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.4.5 GE Healthcare Non-Invasive Prenatal DNA Testing Service Revenue by Product in 2024
11.4.6 GE Healthcare Non-Invasive Prenatal DNA Testing Service Revenue by Application in 2024
11.4.7 GE Healthcare Non-Invasive Prenatal DNA Testing Service Revenue by Geographic Area in 2024
11.4.8 GE Healthcare Non-Invasive Prenatal DNA Testing Service SWOT Analysis
11.4.9 GE Healthcare Recent Developments
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Corporation Information
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.5.4 Thermo Fisher Scientific Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.5.5 Thermo Fisher Scientific Non-Invasive Prenatal DNA Testing Service Revenue by Product in 2024
11.5.6 Thermo Fisher Scientific Non-Invasive Prenatal DNA Testing Service Revenue by Application in 2024
11.5.7 Thermo Fisher Scientific Non-Invasive Prenatal DNA Testing Service Revenue by Geographic Area in 2024
11.5.8 Thermo Fisher Scientific Non-Invasive Prenatal DNA Testing Service SWOT Analysis
11.5.9 Thermo Fisher Scientific Recent Developments
11.6 Perkinelmer
11.6.1 Perkinelmer Corporation Information
11.6.2 Perkinelmer Business Overview
11.6.3 Perkinelmer Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.6.4 Perkinelmer Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.6.5 Perkinelmer Recent Developments
11.7 Qiagen
11.7.1 Qiagen Corporation Information
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.7.4 Qiagen Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.7.5 Qiagen Recent Developments
11.8 Agilent Technologies
11.8.1 Agilent Technologies Corporation Information
11.8.2 Agilent Technologies Business Overview
11.8.3 Agilent Technologies Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.8.4 Agilent Technologies Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.8.5 Agilent Technologies Recent Developments
11.9 Veritas
11.9.1 Veritas Corporation Information
11.9.2 Veritas Business Overview
11.9.3 Veritas Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.9.4 Veritas Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.9.5 Veritas Recent Developments
11.10 BGI Group
11.10.1 BGI Group Corporation Information
11.10.2 BGI Group Business Overview
11.10.3 BGI Group Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.10.4 BGI Group Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Annoroad
11.11.1 Annoroad Corporation Information
11.11.2 Annoroad Business Overview
11.11.3 Annoroad Non-Invasive Prenatal DNA Testing Service Product Features and Attributes
11.11.4 Annoroad Non-Invasive Prenatal DNA Testing Service Revenue and Gross Margin (2020-2025)
11.11.5 Annoroad Recent Developments
12 Non-Invasive Prenatal DNA Testing ServiceIndustry Chain Analysis
12.1 Non-Invasive Prenatal DNA Testing Service Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Non-Invasive Prenatal DNA Testing Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Non-Invasive Prenatal DNA Testing Service Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Non-Invasive Prenatal DNA Testing Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Non-Invasive Prenatal DNA Testing Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Non-Invasive Prenatal DNA Testing Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Non-Invasive Prenatal DNA Testing Service Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Non-Invasive Prenatal DNA Testing Service Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Non-Invasive Prenatal DNA Testing Service Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Non-Invasive Prenatal DNA Testing Service Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Non-Invasive Prenatal DNA Testing Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Invasive Prenatal DNA Testing Service as of 2024)
Table 11. Global Non-Invasive Prenatal DNA Testing Service Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Non-Invasive Prenatal DNA Testing Service Companies Headquarters
Table 13. Global Non-Invasive Prenatal DNA Testing Service Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Non-Invasive Prenatal DNA Testing Service Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Non-Invasive Prenatal DNA Testing Service Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Non-Invasive Prenatal DNA Testing Service Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Non-Invasive Prenatal DNA Testing Service Revenue by Application (2026-2031) & (US$ Million)
Table 21. Non-Invasive Prenatal DNA Testing Service High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Non-Invasive Prenatal DNA Testing Service Growth Accelerators and Market Barriers
Table 25. North America Non-Invasive Prenatal DNA Testing Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Non-Invasive Prenatal DNA Testing Service Growth Accelerators and Market Barriers
Table 27. Europe Non-Invasive Prenatal DNA Testing Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Non-Invasive Prenatal DNA Testing Service Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Non-Invasive Prenatal DNA Testing Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Non-Invasive Prenatal DNA Testing Service Investment Opportunities and Key Challenges
Table 31. Central and South America Non-Invasive Prenatal DNA Testing Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Non-Invasive Prenatal DNA Testing Service Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Non-Invasive Prenatal DNA Testing Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Natera Inc Corporation Information
Table 35. Natera Inc Description and Major Businesses
Table 36. Natera Inc Product Features and Attributes
Table 37. Natera Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Natera Inc Revenue Proportion by Product in 2024
Table 39. Natera Inc Revenue Proportion by Application in 2024
Table 40. Natera Inc Revenue Proportion by Geographic Area in 2024
Table 41. Natera Inc Non-Invasive Prenatal DNA Testing Service SWOT Analysis
Table 42. Natera Inc Recent Developments
Table 43. Illumina Corporation Information
Table 44. Illumina Description and Major Businesses
Table 45. Illumina Product Features and Attributes
Table 46. Illumina Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Illumina Revenue Proportion by Product in 2024
Table 48. Illumina Revenue Proportion by Application in 2024
Table 49. Illumina Revenue Proportion by Geographic Area in 2024
Table 50. Illumina Non-Invasive Prenatal DNA Testing Service SWOT Analysis
Table 51. Illumina Recent Developments
Table 52. Roche Corporation Information
Table 53. Roche Description and Major Businesses
Table 54. Roche Product Features and Attributes
Table 55. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Roche Revenue Proportion by Product in 2024
Table 57. Roche Revenue Proportion by Application in 2024
Table 58. Roche Revenue Proportion by Geographic Area in 2024
Table 59. Roche Non-Invasive Prenatal DNA Testing Service SWOT Analysis
Table 60. Roche Recent Developments
Table 61. GE Healthcare Corporation Information
Table 62. GE Healthcare Description and Major Businesses
Table 63. GE Healthcare Product Features and Attributes
Table 64. GE Healthcare Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. GE Healthcare Revenue Proportion by Product in 2024
Table 66. GE Healthcare Revenue Proportion by Application in 2024
Table 67. GE Healthcare Revenue Proportion by Geographic Area in 2024
Table 68. GE Healthcare Non-Invasive Prenatal DNA Testing Service SWOT Analysis
Table 69. GE Healthcare Recent Developments
Table 70. Thermo Fisher Scientific Corporation Information
Table 71. Thermo Fisher Scientific Description and Major Businesses
Table 72. Thermo Fisher Scientific Product Features and Attributes
Table 73. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 75. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 76. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 77. Thermo Fisher Scientific Non-Invasive Prenatal DNA Testing Service SWOT Analysis
Table 78. Thermo Fisher Scientific Recent Developments
Table 79. Perkinelmer Corporation Information
Table 80. Perkinelmer Description and Major Businesses
Table 81. Perkinelmer Product Features and Attributes
Table 82. Perkinelmer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Perkinelmer Recent Developments
Table 84. Qiagen Corporation Information
Table 85. Qiagen Description and Major Businesses
Table 86. Qiagen Product Features and Attributes
Table 87. Qiagen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Qiagen Recent Developments
Table 89. Agilent Technologies Corporation Information
Table 90. Agilent Technologies Description and Major Businesses
Table 91. Agilent Technologies Product Features and Attributes
Table 92. Agilent Technologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Agilent Technologies Recent Developments
Table 94. Veritas Corporation Information
Table 95. Veritas Description and Major Businesses
Table 96. Veritas Product Features and Attributes
Table 97. Veritas Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Veritas Recent Developments
Table 99. BGI Group Corporation Information
Table 100. BGI Group Description and Major Businesses
Table 101. BGI Group Product Features and Attributes
Table 102. BGI Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. BGI Group Recent Developments
Table 104. Annoroad Corporation Information
Table 105. Annoroad Description and Major Businesses
Table 106. Annoroad Product Features and Attributes
Table 107. Annoroad Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Annoroad Recent Developments
Table 109. Raw Materials Key Suppliers
Table 110. Distributors List
Table 111. Market Trends and Market Evolution
Table 112. Market Drivers and Opportunities
Table 113. Market Challenges, Risks, and Restraints
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Non-Invasive Prenatal DNA Testing Service Product Picture
Figure 2. Global Non-Invasive Prenatal DNA Testing Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Serum Biochemical Index Detection Product Picture
Figure 4. Maternal Peripheral Blood Free DNA Detection Product Picture
Figure 5. Ultrasound Screening Product Picture
Figure 6. Global Non-Invasive Prenatal DNA Testing Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospitals
Figure 8. Medical Institutions
Figure 9. Others
Figure 10. Non-Invasive Prenatal DNA Testing Service Report Years Considered
Figure 11. Global Non-Invasive Prenatal DNA Testing Service Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 13. Global Non-Invasive Prenatal DNA Testing Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Non-Invasive Prenatal DNA Testing Service Revenue Market Share by Region (2020-2031)
Figure 15. Global Non-Invasive Prenatal DNA Testing Service Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Serum Biochemical Index Detection Revenue Market Share by Player in 2024
Figure 18. Maternal Peripheral Blood Free DNA Detection Revenue Market Share by Player in 2024
Figure 19. Ultrasound Screening Revenue Market Share by Player in 2024
Figure 20. Global Non-Invasive Prenatal DNA Testing Service Revenue Market Share by Type (2020-2031)
Figure 21. Global Non-Invasive Prenatal DNA Testing Service Revenue Market Share by Application (2020-2031)
Figure 22. North America Non-Invasive Prenatal DNA Testing Service Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) in 2024
Figure 24. North America Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Non-Invasive Prenatal DNA Testing Service Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) in 2024
Figure 31. Europe Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 34. France Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Non-Invasive Prenatal DNA Testing Service Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 46. India Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Non-Invasive Prenatal DNA Testing Service Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Non-Invasive Prenatal DNA Testing Service Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) in 2024
Figure 54. Central and South America Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Non-Invasive Prenatal DNA Testing Service Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Non-Invasive Prenatal DNA Testing Service Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Non-Invasive Prenatal DNA Testing Service Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) in 2024
Figure 60. South America Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Non-Invasive Prenatal DNA Testing Service Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Non-Invasive Prenatal DNA Testing Service Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Non-Invasive Prenatal DNA Testing Service Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Non-Invasive Prenatal DNA Testing Service Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Non-Invasive Prenatal DNA Testing Service Revenue (2020-2025) & (US$ Million)
Figure 66. Non-Invasive Prenatal DNA Testing Service Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
